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Introduction
G protein–coupled receptors (GPCRs) control a vast number of 
physiological responses including inflammation. The coagulant 
protease thrombin is generated during vascular inflammation, 
and promotes endothelial barrier disruption through activation 
of protease-activated receptor 1 (PAR1; Coughlin, 1994; Soh 
et al., 2010). Thrombin-activated PAR1 couples to G12/13 and 
to Gq signaling effectors RhoA, Ca2+, and PKC to induce endo-
thelial barrier permeability in vitro (McLaughlin et al., 2005; 
Komarova et al., 2007; Soh and Trejo, 2011). Studies using 
endothelium-specific knockout mice have shown that Gq/11 but 
not G12/13 is critical for regulating endothelial barrier permeabil-
ity in response to activation by many GPCRs including PAR1 
(Korhonen et al., 2009). Signaling by p38 MAPK has also been 
implicated in thrombin-induced endothelial barrier permeabil-
ity (Borbiev et al., 2004), but precisely how PAR1 mediates p38 
activation is not known.
All four p38 isoforms (α, β, γ, and δ) are activated 
through the canonical three-tiered kinase cascade mediated by 
upstream MAP3Ks. The canonical cascade converges on two 
MAP2Ks—MKK3 and MKK6—that phosphorylate and ac-
tivate p38 (Raingeaud et al., 1996). However, p38-α isoform 
can also be activated through a noncanonical pathway mediated 
by direct binding of transforming growth factor-β–activated 
protein kinase-1 binding protein 1 (TAB1) to p38-α, bypass-
ing the requirement for MAP2Ks. TAB1 promotes a confor-
mational change in p38, enabling autophosphorylation and 
activation (Ge et al., 2002; De Nicola et al., 2013). However, 
whether GPCRs activate p38 through autophosphorylation and 
the functional implications of this type of noncanonical p38 
signaling is not known.
Posttranslational modifications are essential for regulat-
ing GPCR function. Phosphorylation of GPCRs mediates the 
recruitment of adaptor and regulatory proteins that initiate 
desensitization and internalization. In addition to phosphory-
lation, many GPCRs are modified with ubiquitin. Ubiquitina-
tion of GPCRs is best known to function as a sorting signal for 
lysosomal degradation (Marchese and Trejo, 2013). However, 
not all GPCRs require ubiquitination for sorting to lysosomes 
(Dores and Trejo, 2014). We previously showed that activated 
PAR1 is trafficked to lysosomes through an ubiquitin-indepen-
dent pathway, mediated by the adaptor protein ALIX (Wolfe et 
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al., 2007; Dores et al., 2012). ALIX binds directly to PAR1 via 
a conserved YPXnL motif and facilitates sorting into multivesic-
ular bodies/lysosomes (Dores et al., 2012). We also identified 
a subset of GPCRs with a conserved YPXnL motif including 
the P2Y1 purinergic receptor that may use a similar lysosomal 
sorting pathway (Dores et al., 2012). These studies suggest that 
ubiquitination of certain GPCRs may serve a function distinct 
from lysosomal sorting.
Given that ubiquitination is not required for PAR1 lyso-
somal sorting, we sought to determine if receptor ubiquitination 
modulated signaling responses such as p38 MAPK activation. 
Here, we report that thrombin activation of PAR1 induces non-
canonical p38 activation through autophosphorylation via a 
ubiquitin and TAB1–TAB2–dependent pathway on endosomes. 
We further establish that noncanonical p38 signaling induced 
by PAR1 is critical for the regulation of endothelial barrier 
permeability in vitro and vascular leakage in vivo. The ubiq-
uitin- and TAB1–TAB2–dependent p38 activation pathway is 
conserved for the G protein–coupled purinergic P2Y1 receptor. 
These findings reveal an atypical function for ubiquitination of 
GPCRs in the initiation of noncanonical p38 signaling that is 
critical for the regulation of endothelial barrier disruption.
Results
Ubiquitination of PAR1 is critical for p38 
MAPK activation
We previously showed that agonist stimulation of a ubiquiti-
nation-deficient PAR1 “0K” mutant in which cytoplasmic ly-
sines (K) were converted to arginine (R) displayed comparable 
changes in Gq-mediated phosphoinositide hydrolysis, internal-
ization, and lysosomal degradation (Wolfe et al., 2007; Dores 
et al., 2012). These studies indicate that ubiquitination of PAR1 
is not essential for lysosomal sorting. Despite these observa-
tions, we found that PAR1 wild type (WT) expressed natively 
in endothelial cells or exogenously in HeLa cells is ubiquiti-
nated within minutes of agonist stimulation detected as a high 
molecular weight species using an anti-pan ubiquitin antibody 
(Fig. 1, A and B). To determine the nature of PAR1 ubiquitina-
tion, we used an anti-K63 ubiquitin antibody that specifically 
detects K63-linked ubiquitin chains (Fig. 1 C). Similar to detec-
tion by the anti-pan ubiquitin antibody, the anti-K63 ubiquitin 
specific antibody detected an increase in PAR1 ubiquitination 
after minutes of agonist stimulation (Fig. 1 D). To ensure that 
the ubiquitin signal detected is not due to coassociated ubiquiti-
nated proteins, cells were stimulated with agonist and processed 
using a hot lysis method (Mukai et al., 2010). Agonist induced 
a similar increase in PAR1 ubiquitination under hot lysis condi-
tions (Fig. S1 A). These findings suggest that activated PAR1 is 
modified by K63-linked ubiquitin. However, ubiquitination of 
PAR1 is not required for lysosomal sorting (Dores et al., 2012), 
suggesting that it may serve a distinct function.
To examine the function of PAR1 ubiquitination, we first 
used PAR1 WT and 0K ubiquitin-deficient mutant stably ex-
pressed in HeLa cells (Wolfe et al., 2007; Dores et al., 2012) 
and examined various MAPK signaling cascades after agonist 
stimulation. PAR1 WT and 0K mutant are expressed similarly 
in these cell lines (Fig. S1, B and C). Activation of PAR1 WT 
with thrombin caused a significant increase in p38 phosphoryla-
tion at 7.5 min (Fig. 2 A); however, the response was markedly 
reduced in PAR1 0K–expressing cells (Fig. 2 A). Phosphoryla-
Figure 1. Activated PAR1 is modified with K63-linked ubiquitin. (A) 
Ubiquitination of endogenous PAR1 detected in endothelial cells after 
stimulation with 10 nM α-Th. (B) Ubiquitination of FLAG-tagged PAR1 
WT expressed in HeLa cells after stimulation with 100 µM SFL LRN. 
(C) Poly K63- or K48-linked ubiquitin chains (300 ng each) detected 
with anti-pan ubiquitin (Ub) P4D1 or anti-K63 Ub specific antibodies. 
(D) Ubiquitination of FLAG-tagged PAR1 in HeLa cells after stimulation 
with 100 µM SFL LRN. See Fig. S1 A.
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tion of mitogen- and stress-activated protein kinase 1 (MSK1), a 
downstream p38 substrate, was also reduced in thrombin-treated 
PAR1 0K cells compared with WT cells (Fig. 2 A). However, 
both thrombin-stimulated PAR1 WT and 0K cells displayed 
rapid and comparable increases in extracellular signal regu-
lated kinase 1 and 2 (ERK1/2) phosphorylation (Fig. 2 B) and 
Akt phosphorylation (Fig. S1 D). In vitro p38 kinase activity 
assays also showed a significant loss in thrombin-induced p38 
activation in PAR1 0K versus WT cells (Fig. 2 C). In contrast to 
thrombin, the cytokine tumor necrosis factor-α (TNF) triggered 
a comparable increase in p38 phosphorylation in both PAR1 
WT and 0K HeLa cells (Fig. 2 D), indicating that p38 activation 
is not globally impaired in the PAR1 0K cell line.
We next sought to identify the E3 ubiquitin ligase re-
sponsible for PAR1 ubiquitination using siRNA-mediated 
depletion of neural precursor cell expressed developmentally 
down-regulated protein 4 (NEDD4) family members. The 
NEDD4 family of E3 ubiquitin ligases is known to mediate 
ubiquitination of GPCRs (Marchese and Trejo, 2013). HeLa 
cells expressing PAR1 WT were transiently transfected with 
siRNA targeting NEDD4 E3 ubiquitin ligase family members 
including AIP4, NEDD4-1, NEDD4-2, WWP1, and WWP2 
or nonspecific (ns) siRNA. After 72  h, cells were stimulated 
with agonist, PAR1 was immunoprecipitated, and endogenous 
ubiquitin was detected. Of the NEDD4 family members tested, 
only siRNA-mediated depletion of NEDD4-2 significantly re-
duced agonist-induced PAR1 ubiquitination (Fig. 3, A and B; 
and Fig. S2 A). Similar effects were observed with different 
NEDD4-2 specific siRNAs (Fig. S2, B and C). However, the 
loss of NEDD4-2 expression did not affect basal PAR1 surface 
expression or agonist-promoted internalization (Figs. 3 C and 
S2 D). Depletion of NEDD4-2 also disrupted thrombin-induced 
ubiquitination of endogenous PAR1 in endothelial cells (Fig. 3, 
D and E), whereas basal PAR1 surface expression and ago-
nist-stimulated internalization remained unchanged (Fig. 3 F). 
These findings suggest that NEDD4-2 is a critical mediator of 
agonist-induced PAR1 ubiquitination.
To further explore the role of PAR1 ubiquitination in p38 
activation, NEDD4-2 was depleted from PAR1 WT HeLa cells. 
NEDD4-2 knockdown significantly inhibited thrombin-de-
pendent p38 activation at various time points compared with 
control siRNA transfection (Fig.  4  A). Similar effects were 
observed in cells transfected with different NEDD4-2–specific 
siRNAs and stimulated with thrombin or peptide agonist (Fig. 
S2, E and F). Thrombin-stimulated MSK1 phosphorylation was 
also reduced in NEDD4-2–deficient cells (Fig. 4 A), whereas 
thrombin-dependent ERK1/2 activation was comparable in both 
control and NEDD4-2–depleted cells (Fig. 4 A). Depletion of 
endothelial cell NEDD4-2 expression also inhibited throm-
bin-induced p38 and MSK1 phosphorylation (Fig.  4  B). In 
contrast to thrombin, TNF-induced p38 and MSK1 phosphor-
ylation were similar in control and NEDD4-2–depleted HeLa 
cells (Fig. 4 C), indicating that p38 activation is not globally 
disrupted in NEDD4-2–deficient cells. Together, these data sug-
gest that NEDD4-2–mediated ubiquitination of PAR1 is import-
ant for thrombin-induced p38 activation.
Thrombin induces p38 autophosphorylation
To determine if thrombin activates p38 through the canonical 
three-tiered kinase cascade, we used the p38 inhibitor SB203580, 
which specifically inhibits the catalytic activity of p38-α and -β 
isoforms without blocking p38 phosphorylation mediated by the 
Figure 2. Ubiquitination of PAR1 is required 
for p38 activation. (A and B) HeLa cells express-
ing FLAG-PAR1 WT or ubiquitin-deficient (0K) 
mutant were stimulated with 10 nM α-Th, and 
p38, MSK-1, and ERK1/2 phosphorylation 
was determined. The data (mean ± SD [error 
bars], n = 3) were analyzed using a Student’s t 
test (*, P < 0.05). See Fig. S1 (B–D). (C) PAR1 
WT and 0K HeLa cells were incubated with 
10 nM α-Th, and p38 kinase activity was de-
termined in vitro. The data (mean ± SD [error 
bars], n = 3) were analyzed using a Student’s 
t test (**, P < 0.01). (D) HeLa cells expressing 
PAR1 WT or 0K were stimulated with 10 nM 
α-Th or 16 nM TNF, and p38 phosphorylation 
was determined. The data (mean ± SD [error 
bars], n = 3) were analyzed using a Student’s 
t test (***, P < 0.001).
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upstream kinases (Ge et al., 2002). PAR1 WT HeLa cells or en-
dothelial cells were pretreated with SB203580 before addition 
of an agonist. Thrombin-stimulated p38 and MSK1 phosphory-
lation was virtually abolished in HeLa and endothelial cells pre-
treated with SB203580 (Fig. 5, A and B; and Fig. S3 A), whereas 
ERK1/2 phosphorylation was not affected (Fig. 5, A and B). Sim-
ilar results were observed with the structurally related p38 inhibi-
tor SB202190 (Fig. S3 B). Moreover, thrombin failed to increase 
phosphorylation of MKK3 and MKK6 in both cell types (Fig. 5, 
A and B). However, MKK3/MKK6 phosphorylation was detect-
able after incubation with hyperosmotic NaCl, which triggered 
robust MKK3/MKK6 phosphorylation in SB203580-treated 
and nontreated HeLa cells (Fig. 5 C). In addition, unlike throm-
bin-dependent p38 activation, NaCl-induced p38 phosphoryla-
tion was not inhibited by SB203580 (Fig. 5 C). These findings 
suggest that thrombin-induced p38 activation may occur through 
autophosphorylation and be independent of MKK3 and MKK6.
Ubiquitination of activated PAR1 initiates 
formation of a TAB2–TAB1–p38 signaling 
complex on endosomes
Previous studies showed that the direct binding of TAB1 to 
p38-α MAPK induces autophosphorylation and activation (Ge 
et al., 2002; De Nicola et al., 2013), but whether GPCRs induce 
p38 activation through this pathway is not known. TAB2 is an 
adaptor protein that associates with TAB1 (Bouwmeester et al., 
2004) and contains an Npl4 zinc finger (NZF) domain that binds 
K63-linked ubiquitin (Kulathu et al., 2009). The ubiquitin-bind-
ing properties of TAB2 suggested that it might link TAB1 to 
ubiquitinated PAR1 to promote p38 activation. To investigate a 
role for TAB1 and TAB2 in PAR1 signaling, we first examined 
if TAB2 was recruited to PAR1 on endosomes through a ubiq-
uitin-dependent pathway using TIRF and confocal microscopy 
in live cells. Stimulation of PAR1 WT HeLa cells cotransfected 
with TAB2 WT fused to tdTomato resulted in the rapid forma-
tion of PAR1 endocytic puncta that displayed substantial colo-
calization with TAB2 WT (Fig. 6, A and C) and early endosome 
antigen 1 (EEA1), a marker of early endosomes (Fig. S4, A–D). 
However, TAB2 WT failed to associate with ubiquitination-de-
ficient PAR1 0K mutant after agonist addition (Fig. 6, B and 
C). To test whether the ubiquitin-binding capacity of TAB2 was 
also necessary for recruitment to activated PAR1 WT, the TAB2 
CA mutant defective in ubiquitin binding was used (Kanayama 
et al., 2004). In contrast to TAB2 WT, the TAB2 CA mutant 
fused to tdTomato failed to colocalize with activated PAR1 on 
endocytic punctae (Fig. 6, D–F). These findings suggest that the 
capacity of TAB2 to bind to ubiquitin is critical for its associa-
tion with activated PAR1 on endosomes.
To test the hypothesis that activation of PAR1 promotes 
assembly of a TAB–p38 signaling complex, endogenous PAR1 
Figure 3. Activated PAR1 ubiquitination is mediated by NEDD4-2.  
(A) PAR1 WT or untransfected (UT) HeLa cells were transfected 
with ns, NEDD4-1 (N4-1), or NEDD4-2 (N4-2) siRNA and stim-
ulated with 100 µM SFL LRN. Then PAR1 ubiquitination was de-
tected. See Fig. S2 (A–C). (B) Quantitation of PAR1 ubiquitination. 
The data (mean ± SD [error bars], n = 3) were analyzed using 
a Student’s t test (*, P < 0.05). (C) PAR1 surface expression and 
internalization detected in HeLa cells transfected with ns, N4-1, 
and N4-2 siRNA after 10 min of stimulation with 100 µM SFL LRN. 
The data (mean ± SD [error bars], n = 3) were analyzed using 
a Student’s t test. (D) PAR1 ubiquitination detected in endothelial 
cells transfected with ns or N4-2 siRNAs after stimulation with 10 
nM α-Th. (E) PAR1 ubiquitination was quantitated. The data (mean 
± SD [error bars], n = 3) were analyzed using a Student’s t test 
(*, P < 0.05). (F) PAR1 surface expression and internalization 
determined in endothelial cells transfected with ns or N4-2 siRNA 
after 5 min of 10 nM α-Th. The data (mean ± SD [error bars], 
n = 3) were analyzed using a Student’s t test.
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was immunoprecipitated from thrombin-stimulated endothe-
lial cells, and coassociated proteins were examined. TAB1 
and TAB2 coassociated with activated PAR1 within minutes 
of thrombin stimulation (Fig. 6 G), which also induced the re-
cruitment of p38 MAPK (Fig. 6 G). To confirm p38 complex 
assembly, PAR1 WT HeLa cells were incubated with throm-
bin, phospho-p38 was immunoprecipitated, and coassociated 
proteins were determined. Phospho-p38-α isoform, TAB1, 
and TAB2 were detected in immunoprecipitates from cells 
stimulated with thrombin but not in unstimulated cells or IgG 
control (Fig. 6 H), which is consistent with thrombin-induced 
formation of a TAB2–TAB1–p38-α signaling complex. To test 
whether the ubiquitin-binding capacity of TAB2 was necessary 
for activated PAR1-induced TAB2–TAB1–p38 signaling com-
plex formation, the TAB2 CA mutant defective in ubiquitin 
binding was used (Kanayama et al., 2004). The formation of 
agonist-promoted PAR1-induced TAB1–TAB2 p38 signaling 
complex was reduced in cells exogenously expressing TAB2 
CA mutant compared with WT TAB2 (Fig.  6  I). These find-
ings suggest that PAR1 ubiquitination and the ubiquitin binding 
capacity of TAB2 are required for formation of a p38 MAPK 
endosomal signaling complex.
TAB1 and TAB2 are critical mediators of 
thrombin-induced p38 activation
To define the function of TAB1 in thrombin-stimulated p38 sig-
naling, we used mouse embryonic fibroblasts (MEFs) isolated 
from WT and Tab1−/− homozygous mutant embryos (Inagaki 
et al., 2008). WT MEFs exhibited a marked increase in p38 
activation after thrombin stimulation, whereas p38 activation 
was significantly reduced in Tab1−/−-deficient MEFs (Fig. 7 A). 
In contrast, thrombin-induced ERK1/2 phosphorylation was 
comparable in WT and Tab1−/−-deficient MEFs (Fig. 7 A), in-
dicating that the loss of TAB1 expression specifically disrupts 
thrombin-dependent p38 MAPK activation.
Next, we examined the role of TAB1 and TAB2 versus 
MKK3 and MKK6 in thrombin-induced p38 activation. TAB1, 
TAB2, MKK3, or MKK6 were depleted in PAR1 WT HeLa cells 
using siRNA. The loss of either MKK3 or MKK6 had no sig-
nificant effect on thrombin-stimulated p38 activation compared 
with ns siRNA-transfected cells (Fig. 7 B, lanes 7–10), which 
suggests that neither MKK3 nor MKK6 expression are critical 
mediators of the pathway. Because codepletion of MKK3 and 
MKK6 by siRNA resulted in a marked loss in TAB1 expression 
(Fig. S4 E), we were unable to accurately assess effects on p38 
activation. However, in contrast to the loss of either MKK3 or 
MKK6 expression, depletion of TAB1 alone caused a modest 
but significant decrease in thrombin-stimulated p38 activation, 
whereas loss of TAB2 expression resulted in a marked reduction 
in p38 activation without affecting MKK3 or MKK6 expression 
(Fig. 7 B, lanes 1–6). Thrombin-promoted p38 activation was 
also significantly reduced in endothelial cells depleted of TAB1 
and TAB2 expression (Fig. 7 C), indicating that TAB1 and TAB2 
are critical mediators of thrombin-induced p38 activation.
To confirm that the observed siRNA effects are specific, 
we performed rescue experiments using siRNA-resistant TAB1 
and TAB2. Co-depletion of TAB1 and TAB2 caused a marked 
inhibition of thrombin-dependent p38 activation (Fig.  7  D, 
lanes 1–4). However, coexpression of siRNA-resistant TAB1 
WT and TAB2 WT resulted in significant recovery of throm-
Figure 4. Thrombin-induced p38 activation requires NEDD4-2 expression. (A) PAR1-expressing HeLa cells transfected with ns or NEDD4-2 siRNA were 
stimulated with 10 nM α-Th, and phosphorylation of p38, MSK1, and ERK1/2 was determined. The data (mean ± SD [error bars], n = 3) were analyzed 
using a Student’s t test (*, P < 0.05; **, P < 0.01). See Fig. S2 (D–F). (B) Endothelial cells were transfected with ns or NEDD4-2 siRNAs and incubated 
with 10 nM α-Th. Phosphorylation of p38 and MSK1 was then determined. The data (mean ± SD [error bars], n = 3) were analyzed using a Student’s t test 
(*, P < 0.05; **, P < 0.01). (C) PAR1 HeLa cells transfected with ns or NEDD4-2 (N4-2) siRNAs were treated with 16 nM TNF, and phosphorylation of 
p38 and MSK1 was determined. The data (mean ± SD [error bars], n = 3) were analyzed using a Student’s t test.
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bin-stimulated p38 phosphorylation that was comparable to ns 
siRNA-transfected cells (Fig. 7 D, lanes 2, 4, and 5). These find-
ings indicate that WT TAB1 and TAB2 expression are sufficient 
to restore thrombin-dependent p38 activation. In contrast, coex-
pression of a TAB1 proline 412 to alanine (P412A) mutant that 
blocks interaction with p38-α (Zhou et al., 2006) together with 
TAB2 WT or TAB1 WT together with TAB2 CA mutant failed 
to rescue thrombin-induced p38 activation (Fig. 7 D, lanes 5–8). 
These results suggest that in addition to PAR1 ubiquitination, 
the TAB1 p38 binding motif and ubiquitin-binding properties of 
TAB2 are required for thrombin-induced p38 activation.
Thrombin-induced p38 MAPK signaling 
regulates TAB1 stability
TAB1 activity is modulated by phosphorylation mediated by 
various MAPKs including p38, JNK, and ERK1/2 after cytokine 
stimulation (Cheung et al., 2003; Mendoza et al., 2008). How-
ever, the mechanisms that control TAB1 activity in response to 
GPCR activation are not known. We found that thrombin ac-
tivation of PAR1 caused a significant approximately twofold 
increase in TAB1 expression (Fig. 8 A, lanes 1 and 2), whereas 
TAB2 expression remained unchanged, suggesting that TAB1 
protein stability is dynamically regulated. A significant increase 
in TAB1 expression was also induced after thrombin stimula-
tion of endogenous PAR1 in endothelial cells (Fig. 8 B). To de-
termine whether MAPKs regulate TAB1 expression in response 
to thrombin stimulation, HeLa cells were pretreated with p38 
(SB203580), JNK (SP600125), or MEK1/2 (U0126) inhibitors 
and TAB1 expression was assessed. SB203580 blocked both 
thrombin-mediated p38 activation and increased TAB1 expres-
sion (Fig. 8 A, lanes 1–3), whereas the JNK and MEK1/2 in-
hibitors did not (Fig. 8 A, lanes 1–5). Phos-tag gels were then 
Figure 5. Thrombin-activated PAR1 induces 
p38 autophosphorylation. (A and B) PAR1-ex-
pressing HeLa cells (A) and endothelial cells 
(B) were pretreated with 5 µM SB203580 for 
20 min and then stimulated with 10 nM α-Th, 
and phosphorylation of p38, MSK1, ERK1/2, 
MKK3, and MKK6 was determined. The data 
(mean ± SD [error bars], n = 3) were analyzed 
using a Student’s t test (*, P < 0.05; **, P < 
0.01; ***, P < 0.001). See Fig. S3 (A and 
B). (C) PAR1 HeLa cells were pretreated with 
SB203580 as described above and then in-
cubated with 10 nM α-Th and 400 µM NaCl, 
and phosphorylation of p38, MKK3, and 
MKK6 was determined. The data (mean ± SD 
[error bars], n = 3) were analyzed using a Stu-
dent’s t test (**, P < 0.01).
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used to determine whether thrombin affected the phosphory-
lation status of TAB1 via p38 activation. Thrombin induced a 
marked shift in TAB1 mobility that was virtually abolished by 
SB203580 pretreatment (Fig.  8  C), indicating that p38 is re-
quired for TAB1 phosphorylation. To examine whether regula-
tion of TAB1 expression is mediated by rapid degradation in the 
proteasome, HeLa cells were pretreated with the proteasomal 
inhibitor MG132. Incubation with various concentrations of 
MG132 resulted in a 2.5-fold increase in basal TAB1 protein 
expression compared with DMSO control (Fig.  8  A, lanes 1 
Figure 6. Activation of PAR1 initiates assembly of an ubiquitin-dependent TAB2–TAB1–p38 signaling complex on endosomes. (A and B) PAR1 WT or 0K 
mutant coexpressed with TAB2 WT tdTomato in HEK293 cells were stimulated with 100 µM SFL LRN. Images of live cells at 81 s are shown. Arrowheads 
show PAR1 WT and TAB2 WT containing punctae. PAR1 WT and TAB2 WT colocalization is indicated by black punctae in the merged image. Insets are 
magnifications of the boxed areas. Bars: (main panels) 10 µm; (insets) 2.5 µm. See Fig. S4 (A–D). (C) Quantification of TAB2 WT tdTomato colocalization 
with PAR1 WT (black lines) or 0K mutant (red lines) on endosomes induced by 100 µM SFL LRN. Solid lines represent the mean and the dashed lines rep-
resent the standard deviation. n > 5 cells. (D and E) PAR1 WT coexpressed with either TAB2 WT or CA mutant tdTomato in HEK293 cells were stimulated 
with 100 µM SFL LRN. Arrowheads show PAR1 WT and TAB2 WT positive punctae at 9 min. PAR1 WT and TAB WT containing punctae are indicated by 
black punctae in the merged image. Insets are magnifications of boxed areas. Bars: (main panels) 10 µm; (insets) 2.5 µm. (F) Quantification of PAR1 WT 
colocalization with either TAB2 WT (black lines) or CA mutant (red lines) tdTomato on endosomes induced by 100 µM SFL LRN. Solid lines represent the 
mean and the broken lines represent the standard deviation. n > 5 cells. (G) Endogenous PAR1 was immunoprecipitated from endothelial cells stimulated 
with 10 nM α-Th, and coassociated p38, TAB1, and TAB2 were determined. (H) Phosphorylated p38 was immunoprecipitated from PAR1 HeLa cells stim-
ulated with 10 nM α-Th, and coprecipitated p38-α, TAB1, and TAB2 was detected. (I) PAR1-expressing HeLa cells coexpressing TAB2 WT or CA mutant 
were stimulated with 10 nM α-Th, and coassociated p38, TAB1, and TAB2 were determined.
JCB • VOLUME 210 • NUMBER 7 • 20151124
and 7–10) that was not further increased by thrombin stimu-
lation (Fig. 8 A, lanes 2, 6, and 7). These results suggest that 
TAB1 expression is dynamically regulated through p38-medi-
ated phosphorylation and proteasomal degradation. We specu-
late that TAB1 is protected from proteasomal degradation after 
thrombin activation of PAR1 possibly through recruitment into 
the TAB1–TAB2–p38 endosomal signaling complex.
Ubiquitin-dependent regulation of p38 
activation is conserved for GPCRs
We hypothesize that similar to PAR1, GPCRs containing 
ALIX-binding YPXnL motifs may be modified with ubiquitin 
to facilitate assembly of a p38 signaling complex rather than 
lysosomal degradation. The P2Y1 receptor signals in response 
to the adenine nucleotide ADP and contains a highly conserved 
YPXnL motif (Dores et al., 2012). P2Y1 is also expressed in en-
dothelial cells and promotes inflammatory signaling (Zemskov 
et al., 2011). We therefore examined whether ubiquitination of 
the purinergic P2Y1 receptor is required for p38 MAP kinase 
activation. Agonist activation of P2Y1 expressed in HeLa re-
sulted in a marked increase in receptor ubiquitination (Figs. 9 
A and S5 A). To determine the sites of P2Y1 ubiquitination, 
lysine K341, K353, and K366 residues in the cytoplasmic tail 
were mutated to arginine (R) and designated “K3R.” HeLa 
cells expressing similar amounts of P2Y1 WT and K3R at the 
cell surface (Fig. S5 B) were then stimulated with ADP and 
receptor ubiquitination was assessed. In contrast to WT P2Y1, 
ADP failed to increase ubiquitination of the P2Y1 K3R mu-
tant receptor (Fig.  9  A), indicating that the cytoplasmic tail 
lysine residues are the major sites of agonist-induced P2Y1 
receptor ubiquitination.
We next examined the capacity of the ubiquitin-deficient 
P2Y1 K3R mutant to promote p38 signaling. ADP stimulation of 
P2Y1 WT HeLa cells resulted in a significant increase in phos-
phorylation of p38 and MSK1 compared with untreated and un-
transfected HeLa cells (Figs. 9 B and S5 C). In contrast to P2Y1 
WT, activation of p38 and MSK1 by the P2Y1 K3R mutant was 
markedly reduced (Fig.  9  B), whereas ERK1/2 signaling re-
mained intact. We next examined whether P2Y1 ubiquitination 
is mediated by NEDD4-2 and regulates p38 activation using 
siRNA-targeted depletion of NEDD4-2. In NEDD4-2–deficient 
cells, ADP-stimulated ubiquitination of P2Y1 was significantly 
reduced compared with control siRNA-transfected cells (Fig. 
S5 D), whereas the expression of P2Y1 was not affected (Fig. 
S5, D and E). These results indicate that ADP-induced P2Y1 
ubiquitination is mediated by NEDD4-2. A significant reduc-
Figure 7. TAB1 and TAB2 are required for activated 
PAR1-induced p38 activation. (A) Tab1 WT (+/+) and 
null (−/−) MEFs were stimulated with 10 nM α-Th, and 
phosphorylation of p38 and ERK1/2 was determined. 
The data (mean ± SD [error bars], n = 3) were ana-
lyzed using a Student’s t test (**, P < 0.01). (B) PAR1 
HeLa cells were transiently transfected with ns, TAB1, 
TAB2, MKK3, or MKK6 siRNAs, and stimulated with 
10 nM α-Th. p38 phosphorylation was then deter-
mined. The data (mean ± SD [error bars], n = 3) were 
analyzed using a Student’s t test (*, P < 0.05). See Fig. 
S4 E. (C) Endothelial cells transfected with ns, TAB1, 
and TAB2 siRNA were stimulated with 10 nM α-Th, 
and p38 phosphorylation was examined. The data 
(mean ± SD [error bars], n = 3) were analyzed using 
a Student’s t test (*, P < 0.05; **, P < 0.01). (D) PAR1 
HeLa cells were cotransfected with ns or TAB1 and 
TAB2 siRNA together with pcDNA vector (lanes 1–4); 
siRNA-resistant TAB1 WT, TAB2 WT, or CA mutant 
(lanes 5–6); or siRNA-resistant TAB1 P412A mutant, 
TAB2 WT, or CA mutant (lanes 7–8); and stimulated 
with 10 nM α-Th. The data (mean ± SD [error bars], 
n = 3) were analyzed using a Student’s t test (*, P < 
0.05; **, P < 0.01; ***, P < 0.001).
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tion in ADP-dependent phosphorylation of p38 and MSK1, but 
not ERK1/2, was also observed in NEDD4-2 deficient cells 
(Fig. 9 C). These findings suggest that ubiquitination of P2Y1 is 
required for p38 activation, similar to PAR1.
To investigate whether P2Y1 activation of p38 MAPK 
occurs through autophosphorylation, we used the p38 inhibi-
tor SB203580. ADP stimulation of p38 and MSK1 phosphor-
ylation were significantly inhibited in SB203580-treated P2Y1 
WT HeLa cells compared with control cells (Fig. 9 D), whereas 
ERK1/2 activation was not affected (Fig. 9 D), indicating that 
P2Y1-mediated p38 activation occurs through autophosphory-
lation. Next, the function of TAB1 and TAB2 in P2Y1-induced 
p38 activation was examined using siRNA-targeted depletion. 
A significant decrease in ADP-stimulated p38 and MSK1 phos-
phorylation was detected in cells deficient in TAB1 and TAB2 
expression (Fig. 9 E), which expressed comparable amounts of 
cell surface P2Y1 to the control cells (Fig. S5 F). In addition, a 
significant increase in TAB1 protein expression was detected 
after ADP activation of P2Y1 (Fig.  9  F). These findings pro-
vide evidence that agonist-induced ubiquitination of a subset of 
GPCRs is essential for the initiation of p38 autophosphoryla-
tion and activation mediated through a noncanonical TAB1- and 
TAB2-dependent pathway.
PAR1 regulates endothelial barrier 
permeability through the atypical TAB2–
TAB1–p38 signaling pathway
To assess the function of PAR1-induced ubiquitin and TAB1–
TAB2 p38 activation pathway, we examined whether inhibi-
tion of p38 autophosphorylation affected thrombin-induced 
endothelial permeability in vitro. Confluent monolayers of 
human endothelial cells were pretreated with SB203580 or 
DMSO and then incubated with thrombin. Thrombin induced 
a rapid increase in endothelial barrier permeability in control 
cells (Fig.  10  A), whereas pretreatment with the SB203580 
resulted in a significant inhibition of thrombin-induced per-
meability (Fig. 10 A). To confirm these results, we examined 
thrombin-stimulated HUV EC monolayer gap formation by im-
munofluorescence microscopy using VE-cadherin as a marker 
of adherens junctions. Pretreatment of human umbilical vein 
endothelial cells (HUV ECs) with SB203580 caused signifi-
cant inhibition of thrombin-induced gap formation (Fig. 10 B). 
These findings suggest that p38 mediates thrombin-induced 
endothelial barrier disruption. Next, we examined whether p38 
signaling is required for activated PAR1-induced vascular per-
meability in vivo using mice. The extent of vascular leakage 
measured by the “Miles assay” flux of Evans blue–conjugated 
albumin was minimal in mice pretreated with SB203580 or 
DMSO injected with PBS (Fig. 10 C). However, intradermal in-
jection of the PAR1-specific agonist peptide TFL LRN induced 
a marked increase in leakage of Evans blue compared with PBS 
injected control (Fig. 10 C), which was virtually ablated in mice 
pretreated with SB203580. In contrast, SB203580 failed to af-
fect VEGF-induced vascular leakage (Fig.  10  C), suggesting 
that p38 inhibition is specific to PAR1. Together these findings 
indicate that p38 is a critical mediator of activated PAR1-in-
duced endothelial barrier disruption in vitro and in vivo.
We next examined whether TAB1, TAB2, and NEDD4-2 
mediators of noncanonical p38 activation induced by acti-
vated PAR1 regulate endothelial barrier permeability in vitro. 
The extent of basal permeability detected in TAB1–TAB2 or 
NEDD4-2–deficient endothelial cells was comparable to ns 
siRNA-treated control cells (Fig. 10 D). However, thrombin-in-
duced endothelial barrier permeability was significantly inhib-
ited in endothelial cells lacking TAB1 and TAB2 or NEDD4-2 
expression (Fig. 10 D). Collectively these studies strongly sug-
gest that activated PAR1-stimulated p38 activation occurs via 
an atypical TAB1–TAB2–NEDD4-2–mediated pathway that is 
important for the regulation of endothelial barrier disruption.
Discussion
In this study we define a novel signaling pathway by which ubiq-
uitination of GPCRs is linked to noncanonical activation of p38 
MAPK. We show that ubiquitination of PAR1 is mediated by the 
NEDD4-2 E3 ligase and initiates formation of a TAB2–TAB1–
p38 signaling complex that occurs on endosomes. In addition, 
ubiquitin and TAB-dependent activation of p38 is required for 
thrombin-induced endothelial barrier permeability in vitro. We 
Figure 8. Activation of PAR1 increases TAB1 expression through 
a p38-dependent pathway. (A) PAR1 HeLa cells were pretreated 
for 30 min with DMSO, 5 µM SB203580, 20 µM SP600125, 
10 µM U0126, or varying MG123 concentrations and then stim-
ulated with 10 nM α-Th. TAB1 and TAB2 expression and p38 
phosphorylation were then detected. The data (mean ± SD [error 
bars], n = 3) were analyzed using a Student’s t test (*, P < 0.05). 
(B) HUV ECs were treated with 10 nM α-Th, and TAB1 expression 
was determined. The data (mean ± SD [error bars], n = 3) were 
analyzed using a Student’s t test (**, P < 0.01). (C) PAR1 HeLa 
cells were pretreated with DMSO or 5 µM SB203580 for 30 min 
and stimulated with 10 nM α-Th. Cell lysates were resolved on 
Phos-tag gels to detect TAB1 mobility (indicated by arrows) or 
SDS-PAGE to detect TAB1 and p38.
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further demonstrate that signaling by p38 MAPK is critical for 
PAR1-stimulated vascular leakage in vivo. Induction of nonca-
nonical p38 signaling is not limited to PAR1 since we found that 
ubiquitination of the purinergic GPCR P2Y1 is also required for 
TAB-dependent activation of p38 MAPK. Together these find-
ings establish for the first time a novel function for ubiquitina-
tion of GPCRs in the regulation of p38 MAPK signaling.
Although the canonical three-tiered kinase cascade is 
implicated in p38 MAPK activation induced by many GPCRs, 
the precise mechanism by which inflammatory GPCRs regulate 
p38 activation has not been clearly defined. Noncanonical p38 
activation is induced by direct binding of TAB1 to the C-termi-
nal domain of p38 and requires a critical proline residue P412 
of TAB1 (Ge et al., 2002; Zhou et al., 2006). TAB1 induces a 
conformational change in p38 that triggers autophosphorylation 
of threonine-180 and tyrosine-182 residues present in the acti-
vation loop, which are the same sites phosphorylated by MKK3 
and MKK6 in the canonical pathway (De Nicola et al., 2013). 
Figure 9. P2Y1 receptor-induced p38 activation is mediated by a ubiquitin- and TAB1–TAB2-dependent pathway. (A) HA-tagged P2Y1 WT or K3R mutant 
expressed in HeLa cells were stimulated with 10 µM ADP and ubiquitination was detected. See Fig. S5 (A–C). (B) HA-P2Y1 WT or K3R HeLa cells were 
stimulated with 10 µM ADP, and p38, MSK1, and ERK1/2 phosphorylation was detected. The data (mean ± SD [error bars], n = 3) were analyzed using 
a Student’s t test (*, P < 0.05; **, P < 0.01). (C) HA-P2Y1 HeLa cells transfected with ns or NEDD4-2 siRNA were treated with 10 µM ADP, and p38, 
MSK1, and ERK1/2 phosphorylation was detected. The data (mean ± SD [error bars], n = 3) were analyzed using a Student’s t test (*, P < 0.05; **, 
P < 0.01). See Fig. S5 (D and E). (D) HA-P2Y1 HeLa cells pretreated with DMSO or 5 µM SB203580 for 20 min were stimulated with 10 µM ADP, and 
p38, MSK1, and ERK1/2 phosphorylation was detected. Data (mean ± SD [error bars], n = 3) were analyzed using a Student’s t test (*, P < 0.05; **, 
P < 0.01). (E) HA-P2Y1 HeLa cells transfected with ns or TAB1 and TAB2 siRNA were stimulated with 10 µM ADP, and p38 and MSK1 phosphorylation 
was detected. The data (mean ± SD [error bars], n = 3) were analyzed using a Student’s t test (**, P < 0.01; ***, P < 0.001). See Fig. S5 F. (F) HA-P2Y1 
HeLa cells were stimulated with 10 µM ADP, and TAB1 expression was detected. The data (mean ± SD [error bars], n = 3) were analyzed using a Student’s 
t test (***, P < 0.001).
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However, unlike MKK3 and MKK6, which activate all four p38 
isoforms, TAB1 specifically activates the p38-α isoform (Ge et 
al., 2002; Remy et al., 2010). We discovered that both PAR1 
and P2Y1 promote p38 activation through autophosphorylation, 
since the process was inhibited by SB203580, which blocks 
p38-α and p38-β activity but does not perturb phosphorylation 
of p38 mediated by upstream MAPKs (Davies et al., 2000; Ge 
et al., 2002). The role of TAB1 in p38 activation induced by 
PAR1 was demonstrated using TAB1-deficient MEFs and was 
supported further for both PAR1 and P2Y1 using siRNA-me-
diated ablation of TAB1 expression. We also failed to detect 
phosphorylation of MKK3 or MKK6 after PAR1 activation, 
and depletion of MKK3 or MKK6 by siRNA had no effect on 
thrombin-induced p38 activation. In addition, siRNA knock-
down/rescue studies indicated that expression of siRNA-re-
sistant TAB1 WT was sufficient to restore p38 activation in 
response to thrombin, whereas the TAB1 P412A mutant was 
not. These findings are the first to show that a subset of GPCRs 
activates p38 MAPK through a noncanonical pathway mediated 
by TAB1-dependent p38 autophosphorylation.
Ubiquitination of GPCRs is known to function in ly-
sosomal sorting (Dores and Trejo, 2014). However, not all 
GPCRs require ubiquitination for lysosomal trafficking, in-
cluding PAR1 (Dores et al., 2012). Here we show an atypical 
function for ubiquitination of a subset of GPCRs that is criti-
cal for initiating TAB-dependent p38 activation. We found that 
PAR1 rendered ubiquitin-deficient by either mutation of criti-
cal cytoplasmic lysine residues (Wolfe et al., 2007) or through 
siRNA-mediated depletion of NEDD4-2 resulted in significant 
inhibition of agonist-promoted p38 activation. Similarly, acti-
vation of p38 MAPK by the purinergic P2Y1 receptor requires 
ubiquitination mediated by E3 ligase NEDD4-2.  Under these 
conditions, ERK1/2 signaling remained intact, indicating that 
GPCR ubiquitination is selective for activation of specific sig-
Figure 10. PAR1-mediated endothelial barrier 
disruption requires p38 signaling, NEDD4-2, 
TAB1 and TAB2. (A) Endothelial cells pretreated 
with DMSO or 5 µM SB203580 for 20 min were 
stimulated with 10 nM α-Th, and permeability 
was determined. The data in bar graphs (mean 
± SD [error bars], n = 3) from 30 min is repre-
sentative of three independent experiments and 
were analyzed using a Student’s t test (***, P 
< 0.001). (B) HUV ECs pretreated with DMSO 
or 5 µM SB203580 for 20 min were stimulated 
with 10 nM α-Th for 10 min. Cells were immunos-
tained for VE-cadherin and gap formation was 
determined. The data (mean ± SD [error bars], 
n = 4) were analyzed using a Student’s t test (**, 
P < 0.01). Bars, 10 µm. (C) Mice received intra-
peritoneal injection of PBS or 1 µM SB203580 
before injection of PBS, 4 ng/µl VEGF, or 1 µg/
µl TFL LRN. The data (mean ± SD [error bars], 
n = 10 mice) from three independent experiments 
were analyzed using a Student’s t test (***, P < 
0.001). Bars, 5 mm. (D) Endothelial cells trans-
fected with ns, NEDD4-2 (N4-2), or TAB1 and 
TAB2 (T1/T2) siRNA were stimulated with 10 
nM α-Th, and permeability was determined. Data 
(mean ± SD [error bars], n = 3) in bar graphs are 
representative of three independent experiments 
at 30 min, and were analyzed using a Student’s 
t test (***, P < 0.001).
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naling pathways. We further demonstrate that K63-ubiquitin 
chains are conjugated to PAR1, consistent with NEDD4-2’s 
capacity to modify substrate proteins with K63-linked ubiqui-
tin (Vina-Vilaseca and Sorkin, 2010). However, it is not clear 
why ubiquitin conjugation to PAR1 does not function in sort-
ing the receptor to lysosomes. Our data indicate that the asso-
ciation of TAB2, an adaptor protein that binds to K63-linked 
ubiquitin chains via its NZF domain (Kulathu et al., 2009), 
with PAR1 early in the endocytic pathway requires its ubiq-
uitin-binding domain and may prevent PAR1 interaction with 
ESC RT components on early endosomes. We also found that 
WT TAB2 is rapidly recruited to activated PAR1 WT but not to 
the 0K ubiquitin-deficient mutant and remains associated with 
the receptor during peak p38 activation on endosomes based on 
TIRF microscopy and coimmunoprecipitation experiments. In 
contrast, the capacity of a TAB2 NZF CA mutant defective in 
ubiquitin binding to associate with PAR1 and restore p38 sig-
naling in response to thrombin stimulation was markedly re-
duced. These studies suggest that the ubiquitin-binding capacity 
of TAB2 is essential for association with ubiquitinated PAR1 
and is critical for TAB1-dependent p38 activation. However, 
these studies cannot exclude the possibility that TAB2 associ-
ates indirectly with PAR1 via an intermediary ubiquitin-binding 
protein. While TAB2 and TAB1 have been shown to coasso-
ciate (Bouwmeester et al., 2004), the mechanisms that govern 
their coassociation and function in propagation of p38 signaling 
remain to be determined.
The mechanisms that regulate TAB1 function during GP-
CR-stimulated noncanonical p38 activation are not known. We 
discovered that TAB1 expression was significantly increased 
after activation of PAR1. Several studies indicate that TAB1 
is phosphorylated on C-terminal serine and threonine resi-
dues by JNK, ERK1/2, and p38 MAPK (Cheung et al., 2003; 
Mendoza et al., 2008). We show that PAR1-induced increase 
in TAB1 expression is mediated by p38 and not by JNK or 
ERK1/2. Moreover, p38 phosphorylates TAB1 in response to 
PAR1 activation, which appears to inhibit its rapid degradation 
by the proteasome. In previous studies, TAB1 phosphorylation 
by p38 was shown to inhibit its ability to bind to TAK1, an up-
stream MAP3K (Cheung et al., 2003). Inhibition of the TAB1 
phosphatase DUSP14 also blocked TAB1 dephosphorylation 
and reduced TAK1 activation (Yang et al., 2014). These stud-
ies, and our results, suggest that phosphorylation of TAB1 by 
p38 may specify its function in the noncanonical p38 pathway 
and likely limit its role in TAK1-dependent activation of MKK3 
and MKK6. Intriguingly, MG132 incubation alone caused sub-
stantial accumulation of TAB1 protein in the absence of stim-
ulation, indicating that the TAB1 protein displays high basal 
turnover. An increase in TAB1 expression alone however was 
not sufficient to initiate p38 activation, but rather required ac-
tivation of PAR1. These studies suggest that TAB1 is dynami-
cally regulated through phosphorylation and degradation. The 
recruitment of TAB1 into a signaling complex with activated 
and ubiquitinated PAR1 on endosomes appears to stabilize 
TAB1 expression and is critical for p38 activation.
The physiological importance of TAB1-dependent auto-
phosphorylation and activation of p38 has been demonstrated 
in disease contexts such as interleukin-12 production in mac-
rophages during infection (Kim et al., 2005); myeloid light-
chain induced cardiotoxicity (amyloidosis) in rat, mice, and 
zebrafish models (Shi et al., 2010; Mishra et al., 2013); and 
skin inflammation (Theivanthiran et al., 2015). In skin, the E3 
ligase Itch was shown to regulate p38 signaling by controlling 
the ubiquitination and degradation of TAB1 (Theivanthiran et 
al., 2015). Murine models of myocardial ischemia have also 
shown that p38-α activation is regulated through TAB1-depen-
dent autophosphorylation and contributes to disease progres-
sion (Tanno et al., 2003; De Nicola et al., 2013; Wang et al., 
2013). Importantly, thrombin generation and PAR1 have also 
been implicated in myocardial ischemia, but whether TAB1-de-
pendent p38 activation functions in this pathway is not known. 
Our findings indicate that TAB2-, TAB1-, and NEDD4-2–de-
pendent p38 signaling is critical for activated PAR1-stimulated 
endothelial barrier permeability in vitro and that PAR1-induced 
p38 signaling is essential for vascular leakage in vivo. How-
ever, the mechanisms by which TAB1-dependent p38 signaling 
specifically regulates endothelial barrier disruption require fur-
ther exploration. Both Gq and G12/13 have been linked to throm-
bin-induced endothelial barrier permeability in vitro (Komarova 
et al., 2007). In a previous study, Gq was shown to be critical for 
vascular leakage induced by PAR1 and other GPCRs in vivo, 
rather than G12/13 (Korhonen et al., 2009). PAR1 coupling to 
Gq leads to intracellular Ca2+ mobilization and PKC activation. 
PKC regulates the actin cytoskeleton and disassembly of adher-
ens junctions, which promotes endothelial barrier permeability 
(Komarova et al., 2007). It is not known if components of the 
TAB–p38 signaling pathway are modulated by thrombin-in-
duced mobilization of intracellular Ca2+ or PKC activation, and 
this will be investigated. In addition, the mechanism by which 
PAR1-induced TAB1-stimulated p38 MAPK activation pro-
motes endothelial barrier permeability is not clear but may in-
volve direct effects on adherens junction components that lead 
to disassembly and is an important area for future study.
Materials and methods
Antibodies and reagents
PAR1 agonist peptides (SFL LRN and TFL LRN) were synthesized and 
purified by reverse-phase high-pressure liquid chromatography at Tufts 
University Core Facility. α-Thrombin (α-Th) was purchased from En-
zyme Research Laboratories. ADP was from Acros Organics. TNF-α 
was obtained from EMD Millipore. VEGF was purchased from Pepro-
Tech. Polyclonal rabbit anti-FLAG and -HA antibodies and mouse IgG 
antibody were from Rockland Immunochemicals. Mouse monoclonal 
P4D1 anti-ubiquitin and polyclonal rabbit anti-p38 antibodies were 
from Santa Cruz Biotechnology, Inc. Monoclonal anti-PAR1 WEDE 
antibody was from Beckman Coulter. The monoclonal mouse anti-HA 
antibody was from Covance. The mouse M2 anti-FLAG and -actin an-
tibodies were from Sigma-Aldrich. Polyclonal and monoclonal rabbit 
anti–phospho-ATF2, Akt, phospho-Akt, K63 polyubiquitin, MSK1, 
phospho-MSK1, MKK3, phospho-MKK3, MKK6 and phospho-MKK6, 
NEDD4-1, NEDD4L (also known as NEDD4-2), p38, phospho-p38, 
p38α, p42/44 MAPK, phospho-p42/44 MAPK, VE-cadherin antibodies, 
and ATF2 fusion protein were from Cell Signaling Technology. Mono-
clonal mouse anti-EEA1 was from BD. Monoclonal mouse anti-GAP 
DH antibody was from GeneTex. HRP-conjugated goat–anti-rabbit and 
goat–anti-mouse antibodies were from Bio-Rad Laboratories. Alexa 
Fluor 488–, 594–, and 647–conjugated secondary antibodies were 
from Life Technologies. SB203580 and SB202190 (p38 inhibitors) and 
U0126 (MEK inhibitor) were from LC laboratories. SP600125 (JNK in-
hibitor) and MG132 (proteasomal inhibitor) were from Sigma-Aldrich. 
Phos-Tag was purchased from Wako Pure Chemical Industries. Poly 
K48 and K63 ubiquitin chains were from Boston Biochem.
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Plasmids and cells
N-terminal FLAG-tagged human PAR1 WT and FLAG-PAR1 0K mu-
tant cDNAs were cloned into the mammalian expression vector pBJ, 
and N-terminal HA-tagged PAR1 WT was cloned into pcDNA3.1 as 
described previously (Trejo et al., 2000; Wolfe et al., 2007; Lin and 
Trejo, 2013). Human TAB1 pCMV, and TAB2 pCMV were provided 
by J.  Ninomiya-Tsuji (North Carolina State University, Raleigh, 
NC). N-terminal HA-tagged human P2Y1 pcDNA was obtained from 
R. Nicholas (University of North Carolina). TAB2 Cysteine (C) 670 to 
alanine (A) and C673A pCMV (termed TAB2-CA), TAB1 proline 412 
to A termed “TAB1 P412” pCMV, HA P2Y1 lysines (K) 341, K353, 
and K366 mutated to arginine (R), and pcDNA termed “P2Y1 K3R” 
mutants were generated by QuikChange site-directed mutagenesis 
(Agilent Technologies) and confirmed by dideoxy sequencing. The 
siRNA-resistant TAB1 WT and P412A mutant pCMV and TAB2 WT 
and CA mutant pCMV mutants were also generated by site-directed 
mutagenesis of nucleotides t373c, g375c, t378g, and g381a for TAB1 
and c1044a, t1045a, c1046g, and c1050t for TAB2, and confirmed by 
sequencing. TAB2 WT and TAB2 CA mutant and N-terminal tdTo-
mato were subcloned into pcDNA3.1 using standard techniques. HUV 
ECs were from Lonza Ltd. and maintained according to the manufac-
turer’s instructions. HUV EC-derived EA.hy926 cells and HeLa cells 
were cultured as described previously (Wolfe et al., 2007; Russo et 
al., 2009). HeLa cells stably expressing FLAG-PAR1 WT or FLAG-
PAR1 0K mutant pBJ were generated by cotransfection with hygro-
mycin resistance vector, and screened by cell surface ELI SA. Cells 
were grown and maintained as described previously (Wolfe et al., 
2007). Immortalized MEFs from WT (Tab1+/+) and mutant (Tab1−/−) 
embryos isolated from heterozygous Tab1 floxed mice, in which the 
loxP sites flanked exons 9 and 10 to remove the C-terminal region of 
TAB1 protein, were maintained as previously described (Inagaki et al., 
2008). HEK293 cells were cultured as described previously (Soohoo 
and Puthenveedu, 2013).
Transfections and siRNA
Cells were transfected with plasmids and siRNAs using Lipofect-
amine 2000 and Oligofectamine, respectively, according to the man-
ufacturer’s instructions (Life Technologies). NEDD4.1, NEDD4L 
(NEDD4.2) SMA RTpool, WWP1 SMA RTpool, and AIP4 (5′-GGU 
GACAA AGAGC CAACA GAG-3′) were used at 50 nM and purchased 
from GE Healthcare. WWP2 Stealth siRNA was used at 50 nM and 
obtained from Life Technologies. NEDD4-2 #7 siRNA (5′-AAG 
AAUAU CGCUG GAGAC UCU-3′) and #9 (5′-AAG AUCAU AACAC 
AAAGA CUA-3’) siRNA were used at 25 nM. TAB1 (5′-CGG CUAUG 
AUGGC AACCGA-3′) used at 12.5 nM, MKK3 (5′-GGA UAUCC 
UGCAU GUCCAA-3′) used at 12.5 nM, MKK6 (5′-GGG CCACC 
GUGAA CUCACA-3′) used at 50 nM, TAB2 siRNA (5′-CCU CCAGC 
ACUUC CUCUUC-3′) used at 50 nM, and ns siRNA (5′-GGC UACGU 
CCAGG AGCGC ACC-3′) were all obtained from QIA GEN. The TAB 
knockdown rescue experiments were performed by transfecting HeLa 
cells with ns or TAB1–TAB2-specific siRNAs for 48  h.  Cells were 
then washed with starvation buffer DMEM containing 1 mg/ml BSA, 
10 mM Hepes, and 1 mM CaCl2 and transfected with either 150 ng of 
pcDNA3.1 or 150 ng of TAB1 WT or P412A pCMV combined with 
either TAB2 WT or TAB2 CA mutant using Lipofectamine 2000 and 
incubated for an additional 24 h.
MAPK signaling assays
Serum-starved cells were treated under various conditions. Equivalent 
amounts of cell lysates were resolved by SDS-PAGE, transferred to 
membranes, and probed with specific antibodies. Membranes were de-
veloped by chemiluminescence and quantified by densitometry. In vitro 
p38 kinase assays were performed according to the manufacturer’s in-
structions (Cell Signaling Technology).
Phos-tag gels
Phosphorylation of p38 MAPK was detected using Phos-tag gels con-
taining 100 µM Phos-Tag acrylamide and 100 µM MgCl2 according to 
the manufacturer’s instructions (Wako Pure Chemical Industries).
Immunoprecipitations and ubiquitination
PAR1 and P2Y1 receptor immunoprecipitation and ubiquitination ex-
periments were performed essentially as described previously (Chen et 
al., 2011; Dores et al., 2012). HeLa cells or endothelial EA.hy926 cells 
were grown in 6 cm dishes and starved overnight. Serum-starved cells 
were stimulated with agonists for the indicated times at 37°C.  Cells 
were lysed in RIPA buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS 
with 50 mM β-glycerophosphate, 10 µg/ml leupeptin, aprotinin, tryp-
sin protease inhibitor, pepstatin, 100 µg/ml benzamide, and 20  mM 
N-ethylmaleimide. Samples were passed through a 21 GA needle and 
cleared by centrifugation. Protein concentrations were determined with 
a bicinchoninic acid assay and equivalent amounts of lysates were used 
for immunoprecipitations using anti-PAR1 WEDE or anti-HA antibod-
ies. Immunoprecipitates were eluted with 2× Laemmli sample buffer 
containing 200 mM dithiothreitol. Coimmunoprecipitations were per-
formed as described above except that cells were lysed in Triton lysis 
buffer containing 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1% Triton 
X-100, 5 mM EDTA, 50 mM NaF, and 50 mM β-glycerophosphate, 
supplemented with protease inhibitors and 20 mM N-ethylmaleimide 
and processed as described for ubiquitination immunoprecipitations.
Confocal and TIRF microscopy
HUV ECs grown on coverslips were stimulated with agonists, fixed 
with 4% paraformaldehyde, permeabilized with methanol, and immu-
nostained with a primary rabbit anti–VE-cadherin antibody, secondary 
anti–rabbit Alexa Fluor 488 antibody, and costained with 4’,6-diamidi-
no-2-phenylindole. HeLa cells expressing FLAG-PAR1 grown on cov-
erslips were stimulated with agonists, fixed with 4% paraformaldehyde, 
permeabilized with 0.1% Triton X-100, and immunostained with a pri-
mary rabbit anti-TAB2 and mouse anti-EEA1 antibodies, and secondary 
anti–rabbit Alexa Fluor 488 and anti–mouse Alexa Fluor 647 antibodies. 
Images for both the HUV EC and HeLa cell experiments were acquired 
using a two-color microscope (IX81 ZDC2; Olympus) equipped with 
an UPlanFL N 20×/0.50 NA objective lens (1.6 NA; Olympus) and a 
CoolSNAP H2Q CCD camera (Photometrics). Images were collected 
using MetaMorph 7.7 software (Molecular Devices). To quantify gap 
junctions, binary masks were generated for all images using a fluores-
cence intensity threshold that allowed for discrimination between cells 
and gaps. MetaMorph’s Integrated Morphometry Analysis tool was used 
to calculate the mean gap area for each image’s binary mask. Data from 
four independent experiments were analyzed, with each experiment in-
cluding 16 images per treatment. Average gap areas were normalized 
to the thrombin/DMSO condition. Pearson’s correlation coefficients 
(r) for quantifying colocalization of PAR1 with either EEA1 or TAB2 
tdTomato were calculated for 12 different cells from multiple indepen-
dent experiments using SlideBook 4.2 software. TIRF live-cell imaging 
was performed in HEK293 cells expressing PAR1 and TAB2 tdTomato. 
PAR1 was labeled with Alexa Fluor 488–conjugated M1-FLAG anti-
body. Imaging was performed at 37°C using an inverted microscope 
(Eclipse Ti; Nikon) equipped with a 100× 1.49 NA TIRF objective lens 
in a temperature and CO2 controlled chamber. The confocal experiments 
were performed using the 100× objective lens and images were acquired 
every 30  s.  The images were acquired using cell imaging software 
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(Andor iQ) on an electron-multiplying charge-coupled device camera 
(iXon +897; Andor) with 488 and 561 solid-state lasers as light sources 
as described previously (Soohoo and Puthenveedu, 2013). Data were an-
alyzed using ImageJ, Imaris, and MAT LAB software (MathWorks). Ob-
jective-based detection of PAR1 and TAB2 objects was identified using 
the Spots tracking algorithm in Imaris (Bitplane). Spots were identified 
using local background subtraction and filtered using the quality fil-
ter. Each object for the confocal images was manually verified while 
blinded from the other channel. TIRF images were not all manually 
verified, but were optimally filtered. Colocalization was determined by 
using the Matlab Imaris plug-in Colocalize Spots with a threshold of 
0.5 voxels. This is an object-based colocalization plug-in that considers 
two spots to be colocalized when their centers are 0.5 voxels apart or 
closer. The number of colocalized spots over the total number of spots 
per time frame was plotted to give percent colocalization.
Cell surface ELI SA
Cell surface expression of PAR1 and P2Y1 receptor was measured by 
ELI SA (Soto and Trejo, 2010). Cells were fixed with 4% paraformal-
dehyde before incubation with primary antibody followed by second-
ary HRP-conjugated antibody. The amount of antibody bound to the 
cell surface was determined by incubation with one-step 2,2’-azino-
bis-3-ethylbenzthiazoline-6-sulfonic acid (Thermo Fisher Scientific) 
substrate for 10–20 min at room temperature. An aliquot was removed 
and the absorbance at 405 nm was determined using a microplate 
reader (SpectraMax Plus; Molecular Devices).
Endothelial barrier permeability
Endothelial barrier permeability was quantified by measuring the flux 
of Evans blue–bound BSA as described previously (Russo et al., 2009). 
Endothelial EA.hy926 cells were seeded into 3.0 µM transwell permea-
bility support chambers (Corning) and grown for 3–5 d until confluent. 
The cells were starved overnight and treated as indicated. Evans blue 
conjugated to BSA was added to the upper chamber after 10 min of 
agonist stimulation. Samples were removed from the lower chamber at 
the indicated time points and the amount of Evans blue diffusion was 
quantified by measuring the absorbance at 605 nm using a microplate 
reader (SpectraMax Plus; Molecular Devices).
Vascular permeability assay
Vascular permeability was measured in vivo as described previously 
with minor modifications (Korhonen et al., 2009). In brief, 8-wk-old 
CD1/CD1 female mice were anesthetized and injected intraperitoneally 
with 100 µl of PBS or 1 µM SB203580. After 1 h, mice were anes-
thetized again and injected in the tail vein with 200  µl of 1.0% Ev-
an’s blue–0.1% BSA diluted in PBS. After 1 min, 50 µl of 0.1% BSA 
in PBS, 4 ng/ µl VEGF, or 1 µg/µl TFL LRN (PAR1-specific agonist 
peptide) were injected intradermally into separate areas of the shaved 
back skin of the mouse. The mice were sacrificed 10 min after injection 
and 8 mm of skin containing the site of injection was removed. The 
skin biopsies were incubated in 500 µl of formamide at 65°C for 24 h, 
and the amount of extracted Evan’s blue dye was measured using a 
spectrophotometer at OD 595 nm. Animal studies were performed in 
accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health under 
protocols approved by the Institutional Animal Care and Use Commit-
tee (IAC UC) at the University of California, San Diego.
Statistical analysis
Data were analyzed using Prism software (version 4.4; Graph-
Pad Software). Statistical significance was determined by per-
forming a Student’s t test.
Online supplemental material
Fig. S1 shows PAR1 ubiquitination with the hot lysis method, PAR1 
WT and 0K mutant expression, and α-Th–induced Akt phosphory-
lation in PAR1 WT and 0K HeLa cells. Fig. S2 shows E3 ubiquitin 
ligase mini-screen and loss of α-Th and SFL LRN-induced PAR1 ubiq-
uitination in HeLa cells transfected with NEDD4-2 SMA RTpool and 
individual siRNAs. Fig. S3 shows inhibition of α-Th–stimulated p38 
phosphorylation in HUV ECs pretreated with SB203580 and PAR1 
HeLa cells pretreated with SB202190. Fig. S4 shows PAR1, TAB2, and 
EEA1 colocalization and TAB1 expression in HeLa cells depleted of 
MKK3 and MKK6 expression. Fig. S5 shows ADP-induced HA-P2Y1 
WT ubiquitination but not 3KR mutant ubiquitination and surface ex-
pression in HeLa cells. ADP-induced p38 activation in P2Y1 WT HeLa 
cells but not in untransfected cells is also shown. P2Y1 receptor surface 
expression is not changed in NEDD4-2 and TAB1–TAB2 siRNA de-
pleted HeLa cells. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.201504007/DC1.
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